Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Non-Current Debt (2016 - 2019)

Fate Therapeutics (FATE) has disclosed Non-Current Debt for 8 consecutive years, with $9.5 million as the latest value for Q2 2019.

  • For the quarter ending Q2 2019, Non-Current Debt fell 26.23% year-over-year to $9.5 million, compared with a TTM value of $9.5 million through Jun 2019, down 26.23%, and an annual FY2018 reading of $12.4 million, down 15.95% over the prior year.
  • Non-Current Debt was $9.5 million for Q2 2019 at Fate Therapeutics, down from $11.0 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $16.4 million in Q1 2015 and bottomed at $1.1 million in Q1 2017.
  • Average Non-Current Debt over 5 years is $10.3 million, with a median of $11.3 million recorded in 2018.
  • The sharpest move saw Non-Current Debt crashed 87.57% in 2017, then soared 1201.48% in 2018.
  • Year by year, Non-Current Debt stood at $10.7 million in 2015, then plummeted by 76.6% to $2.5 million in 2016, then skyrocketed by 492.08% to $14.8 million in 2017, then dropped by 15.95% to $12.4 million in 2018, then fell by 23.92% to $9.5 million in 2019.
  • Business Quant data shows Non-Current Debt for FATE at $9.5 million in Q2 2019, $11.0 million in Q1 2019, and $12.4 million in Q4 2018.